TReAT – A Platform for the Specific Regeneration of Antiviral T-Cell Responses in a Novel Personalized Therapeutic Approach

A Platform for the Specific Regeneration of Antiviral T-Cell Responses in a Novel Personalized Therapeutic Approach

Viral infections pose a significant risk to high-risk patients, often leading to severe illness and death despite antiviral therapies. In immunosuppressed patients, reducing immunosuppression can help combat infections but frequently results in undesirable immune reactions, such as autoimmunity. The “TReAT” project aims to develop patient-specific T-cell therapies that effectively control viral infections while suppressing unwanted immune responses. These T cells are designed to be resistant to immunosuppressants, enabling personalized treatments. The initiative is part of the BMBF funding program for personalized medicine, bringing together science and industry to drive clinical innovations.

Subproject at DRFZ:

Molecular Deep Characterization of Tacrolimus-Resistant Antiviral T-Cell Products